Идёт набор NCT07520747

A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea

— Наблюдательное Inflammatory Bowel Diseases

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально: Состояния в реестре: Inflammatory Bowel Diseases. Базовые параметры: до 17 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: South Korea
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Epidemiology, Treatment Patterns, and Healthcare Resource Utilization in Pediatric Patients Under 18 Years of Age With Inflammatory Bowel Diseases in Korea: A Claims Database Study

Обзор

The purpose of this study is: * to find out out the number of children who develop crohn's disease (CD) and ulcerative colitis (UC) each year and are living with the disease and to see how this differs by age groups. * to understand how children of different age groups are treated over time and how their treatment changes as they grow. * to assess how often children use healthcare services and how much this costs for different age groups over several years. CD and UC are long-term diseases that cause inflammation in intestine (part of digestive system) and develop ulcers.

Первичные конечные точки

Crude and Age-Adjusted Annual Incidence in Pediatric Crohn's Disease (CD) [Срок оценки: During the index period (2012 to 2023; up to 12 years)]
Crude and Age-Adjusted Annual Incidence in Pediatric Ulcerative Colitis (UC) [Срок оценки: During the index period (2012 to 2023; up to 12 years)]
Crude and Age-Adjusted Annual Prevalence in Pediatric CD [Срок оценки: During the index period (2012 to 2023; up to 12 years)]
Crude and Age-Adjusted Annual Prevalence in Pediatric UC [Срок оценки: During the index period (2012 to 2023; up to 12 years)]
Incidence of CD by Age-Stratified Groups [Срок оценки: During the index period (2012 to 2023; up to 12 years)]
Incidence of UC by Age-Stratified Groups [Срок оценки: During the index period (2012 to 2023; up to 12 years)]
Prevalence of CD by Age-Stratified Groups [Срок оценки: During the index period (2012 to 2023; up to 12 years)]
Prevalence of UC by Age-Stratified Groups [Срок оценки: During the index period (2012 to 2023; up to 12 years)]
Percentage of Participants Whose Primary Diagnosis Switched Between CD and UC [Срок оценки: During the index period (2012 to 2023; up to 12 years)]
Initial Treatment Types by Age-Stratified Group [Срок оценки: From index date to follow-up (Up to 13 years)]

Критерии участия

Критерии включения

Participants with at least two outpatient or one inpatient diagnosis codes for the same disease type (either CD or UC) using international classification of diseases, tenth revision (ICD-10) codes (K50. X for CD and K51. X for UC) recorded as primary or the first secondary diagnosis, and the codes for rare and intractable disease registration program (V130 for CD, V131 for UC) during the index period
Participants who received at least one prescription for conventional pediatric inflammatory bowel disease (IBD)-related medications (for example, 5-aminosalicylic acids \[5-ASAs\], exclusive enteral nutrition \[EENs\], corticosteroids, immunomodulators, or biologic drugs) during the index period